Clinical Utility of Serum C-Peptide Concentration for Hospitalized Patients with Hyperglycemia
Authors' conclusion
C-peptide concentration did not exhibit a robust predictive capability for future need of insulin therapy and achieving glycemic control, limiting its utility in clinical practice within inpatient settings.
Study context
- Population
- Adults admitted to Mayo Clinic inpatient facilities for an acute hyperglycemic emergency, January 2017–November 202263 women
- Participants
- 187 adults
- Exposure
- Insulin need at follow-up vs no insulin need
- Outcome
- Predictive capacity of C-peptide for discontinuation of therapeutic insulin
Main finding
As reported in the abstract
Initial C-peptide concentration
- Initial C-peptide concentrations did not differ between patients requiring insulin during follow-up and those who did not
- Insulin therapy during follow-up vs No insulin: P = 0.16
Observational data: associations, not effects.
Further findings
Serum C-peptide in patients with T1D antibodies · during hospitalization
- Diminished serum C-peptide with T1D antibodies
- P = 0.014
- Inverse correlation with subsequent HbA1c%
- r = (−0.22), P = 0.005
Prediction of glycemic control
- C-peptide showed limited predictive capacity for achieving glycemic control
Subgroup: non-autoimmune non-pancreatitis diabetes (NANP-DM)
- Similar limited capacity for anticipating insulin needs and achieving glycemic control
Original publication
Clinical Utility of Serum C-Peptide Concentration for Hospitalized Patients with Hyperglycemia. Diabetes Technol Ther. Published 20 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →